Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WuXi Biologics (Cayman)WXIBF 98 3-Year EBITDA Growth Rate is 13.80% as of Dec. 2025, which is 77% below its 10-year median of 60.60. GuruFocus rates WXIBF with a GF Scoreâ„¢ of 98/100 and a GF Valueâ„¢ of $5.29 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 1,130 Biotechnology companies, WuXi Biologics (Cayman) ranks worse than 51.68% on this metric.
During the past 12 months, WuXi Biologics (Cayman)'s average EBITDA Per Share Growth Rate was 44.20% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 13.80% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 22.30% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 47.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of WuXi Biologics (Cayman) was 79.40% per year. The lowest was 9.10% per year. And the median was 60.60% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
WuXi Biologics (Cayman) 3-Year EBITDA Growth Rate Related Terms
WXIBF vs VRTX, REGN, RVMD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, WuXi Biologics (Cayman)'s 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi Biologics (Cayman) 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where WuXi Biologics (Cayman)'s 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 13.80% mean?
WuXi Biologics (Cayman) (WXIBF) has a 3-Year EBITDA Growth Rate of 13.80% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for WuXi Biologics (Cayman) and its competitors. This is 77% below median its historical median of 60.60. Over the past decade, WuXi Biologics (Cayman)'s 3-Year EBITDA Growth Rate has ranged from 9.10 to 79.40. According to the industry distribution chart, WuXi Biologics (Cayman) ranks #584 out of 1130 companies in the Biotechnology industry, placing it in the top 51.7%.
Is WuXi Biologics (Cayman)'s 3-Year EBITDA Growth Rate too high?
WuXi Biologics (Cayman)'s current 3-Year EBITDA Growth Rate of 13.80% is 77% below median its 10-year median of 60.60. Over the past 10 years, this metric has ranged from a low of 9.10 to a high of 79.40. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.85. WuXi Biologics (Cayman)'s value of 13.80% is 7.1% below this industry median. Based on the distribution chart, WuXi Biologics (Cayman) ranks #584 out of 1130 companies in the Biotechnology industry, which is below the industry midpoint. Overall, WuXi Biologics (Cayman) has a GF Scoreâ„¢ of 98/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does WuXi Biologics (Cayman)'s 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, WuXi Biologics (Cayman) ranks #584 out of 1130 companies for 3-Year EBITDA Growth Rate. This places WuXi Biologics (Cayman) in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.85. WuXi Biologics (Cayman)'s value of 13.80% is 7.1% below this benchmark. Historically, WuXi Biologics (Cayman)'s own 3-Year EBITDA Growth Rate has ranged from 9.10 to 79.40 over the past decade. While the company's 10-year median is 60.60 vs. the industry median of 14.85, WuXi Biologics (Cayman) has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,130 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. WuXi Biologics (Cayman)'s current 3-Year EBITDA Growth Rate of 13.80% is 7.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for WuXi Biologics (Cayman) and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WuXi Biologics (Cayman)'s current 3-Year EBITDA Growth Rate is 13.80%, which is 77% below median its own 10-year median of 60.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi Biologics (Cayman) stock overvalued right now?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) (WXIBF) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.29, compared to a current price of $6.20 — trading 17.2% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 13.80%, which is 77% below median its 10-year median of 60.60 and 7.1% below the Biotechnology industry median of 14.85. WuXi Biologics (Cayman)'s overall GF Score™ is 98/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For WuXi Biologics (Cayman) (WXIBF), the current 3-Year EBITDA Growth Rate is 13.80% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is WuXi Biologics (Cayman) (WXIBF) Overvalued in 2026?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) stock appears to be overvalued.
The current stock price of $6.20 is trading 17.2% above its estimated GF Value™ of $5.29.
GuruFocus considers WuXi Biologics (Cayman) to be Modestly Overvalued.
Key valuation signals for WXIBF:
3-Year EBITDA Growth Rate: 13.80% (77% below median its 10-year median of 60.60)
GF Value™: $5.29 vs. price of $6.20 (17.2% above fair value)
Industry Position: 7.1% below the Biotechnology median (#584 of 1130)
No single metric tells the full story. See the WXIBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing refining and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
98GF Score
Get the complete analysis for WXIBF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WXIBF has been successfully added to your 
